Notice of Cipher Pharmaceuticals Inc. Q1 2013 Conference Call and 2012 Annual and Special Meeting of Shareholders
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, April 15, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) today announced it will host a conference call for its Q1 2013 financial results and hold its Annual and Special Meeting of Shareholders on Friday, May 3, 2013.
Q1 2013 CONFERENCE CALL
WHEN: Friday, May 3, 2013 at 8:30AM ET
CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://bit.ly/XUdD6c. An archived replay of the webcast will be available for 365 days.
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
WHEN: Friday, May 3, 2013 at 11:00AM ET
WHERE: Goodmans LLP, Bay Adelaide Centre, 333 Bay Street, Suite 3400, Toronto, Ontario
WEBCAST: The meeting will be webcast live. To access the webcast go to http://www.cipherpharma.com or http://bit.ly/ZN3zX9. Please connect at least 15 minutes prior to the start of the meeting to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may choose to market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed five marketing partnerships, generating growing licensing revenue.
SOURCE: Cipher Pharmaceuticals Inc.
For further information:
Craig Armitage
Investor Relations
TMX Equicom
(416) 815-0700 ext 278
(416) 815-0080 fax
[email protected]
Larry Andrews
President and CEO
Cipher Pharmaceuticals
(905) 602-5840 ext 324
(905) 602-0628 fax
[email protected]
Share this article